ecopipam has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y; Liu, X; Mishra, PK; Patel, KP; Zheng, H | 1 |
| Astrup, A; Greenway, FL; Kwan, R; Lachowicz, J; Ling, W; Pedicone, L; Strader, CD | 1 |
1 trial(s) available for ecopipam and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects.
Topics: Adolescent; Adult; Aged; Benzazepines; Body Mass Index; Diabetes Mellitus, Type 2; Dopamine Antagonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Patient Selection; Placebos; Weight Loss | 2007 |
1 other study(ies) available for ecopipam and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Attenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetes.
Topics: Animals; Benzazepines; Blood Glucose; Diabetes Mellitus, Type 2; Dopamine; Dopamine Antagonists; Gene Expression Regulation; Paraventricular Hypothalamic Nucleus; Raclopride; Rats; Receptors, Dopamine; Sympathetic Nervous System | 2014 |